David Krempa - 12 Jun 2025 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
Chief Business Officer
Signature
/s/ James R. Gruber
Issuer symbol
ETON
Transactions as of
12 Jun 2025
Net transactions value
-$504,318
Form type
4
Filing time
16 Jun 2025, 16:56:08 UTC
Previous filing
06 Jan 2025
Next filing
12 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Krempa David Chief Business Officer C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK /s/ James R. Gruber 16 Jun 2025 0001968254

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETON Common Stock Sale $253,297 -16,977 -2.6% $14.92 629,669 12 Jun 2025 Direct F1, F4
transaction ETON Common Stock Sale $100,436 -6,800 -1.1% $14.77 622,869 13 Jun 2025 Direct F2, F4
transaction ETON Common Stock Sale $150,585 -10,223 -1.6% $14.73 612,646 16 Jun 2025 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold in multiple trades at prices ranging from $14.77 to $14.98. The price reported above reflects the weighted average sales price.
F2 The shares were sold in multiple trades at prices ranging from $14.75 to $14.81. The price reported above reflects the weighted average sales price.
F3 The shares were sold in multiple trades at prices ranging from $14.50 to $14.79. The price reported above reflects the weighted average sales price.
F4 The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

The Reporting Person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.